May 22, 2018 / 12:59 PM / a month ago

BRIEF-Sanofi Says FDA To Review Zynquista As Potential Treatment For Type 1 Diabetes

* FDA TO REVIEW ZYNQUISTA™ (SOTAGLIFLOZIN) AS POTENTIAL TREATMENT FOR TYPE 1 DIABETES

* SANOFI - TARGET FDA ACTION DATE UNDER PRESCRIPTION DRUG USER FEE ACT (PDUFA) IS ANTICIPATED TO BE MARCH 22, 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below